Early treatment with infliximab in patients with juvenile idiopathic arthritis

Results At 54 week 100% and 87.5% patients with early and long-standing JIA respectively achieved at least 50% response. After 2 years ACR-Pedi 70/90 response to infliximab was recorded in all patients with early JIA and 100%/88.9% of patients with long-standing JIA respectively. At weeks 54 following infliximab treatment, 89% and 60% of patients with early and long-standing JIA achieved remission. At the end of the second year, remission was reported in 97% of children with early JIA and 72% of patients in the second group. 34% of the patients discontinued due to an adverse event, mainly lack of efficacy (23 patients) and hypersensitivity reactions (11 patients).